Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 3 Stomatitis 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Mucositis 2 Mouth Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Small Cell 2 Brain Neoplasms 2 Spinal Cord Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 187 Fluorouracil 150 Leucovorin 135 Cetuximab 127 Irinotecan 114 Oxaliplatin 108 pembrolizumab 96 Capecitabine 82 IFL protocol 53 Panitumumab 43 Nivolumab 43 regorafenib 42 Folfox protocol 39 Gemcitabine 30 trifluridine tipiracil drug combination 27 Cisplatin 24 Carboplatin 24 atezolizumab 23 Pemetrexed 20 Paclitaxel 20 Drug Therapy 20 130-nm albumin-bound paclitaxel 17 Trastuzumab 14 encorafenib 13 Trifluridine 13 Ipilimumab 13 HMPL-013 13 tislelizumab 12 spartalizumab 11 Docetaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colorectal Neoplasms × RRx-001 × Clear all

NCT02096354 2024-10-15

ROCKET

EpicentRx, Inc.

Phase 2 Completed

62 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡